<b><i>Introduction:</i></b> Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients’ persistence on treatment, in a real-world setting. <b><i>Methods:</i></b> Data were extracted from de-identified electronic medical records from an obesity management clinic in Switzerland. Changes in body weight and blood pressure were evaluated in the full cohort (<i>N</i> = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (<i>n</i> = 236), 7 months (<i>n</i> = 159), or 12 months (<i>n</i> = 71). <b><i>Results:</i></b> Median persistence on liraglutide was 6.8 months. Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg. Mean 7-month weight change from baseline in the full cohort was −4.1 kg (95% confidence interval: −5.0, −3.2; <i>p</i> < 0.001; −4.2%). Weight change was −4.4 kg (−4.7%) in the ≥4-month persistence subgroup at 4 months, −5.1 kg (−5.3%) in the ≥7-month persistence subgroup at 7 months, and −7.5 kg (−7.1%) in the ≥12-month persistence subgroup at 12 months (all <i>p</i> < 0.001). In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively. Weight loss did not differ significantly according to history of bariatric surgery (<i>p</i> = 0.94). Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; <i>p</i> = 0.018), with no significant changes in systolic blood pressure. Approximately two-thirds of patients did not have health insurance that could cover the cost of liraglutide. <b><i>Conclusion:</i></b> In a real-world setting with low insurance coverage and with most patients not reaching the recommended maintenance dose of 3.0 mg, the use of liraglutide, in combination with diet and exercise, was associated with clinically meaningful weight loss.
TCT-117 Performance and Safety of the Resorbable Magnesium Scaffold, Magmaris, in a Real-World Setting: Primary and Secondary Endpoint Analysis of the Full Cohort (2,066 Subjects) of the BIOSOLVE-IV Registry
